It was a pleasure to speak with Marina Magrey (Case Western Reserve University School of Medicine/ MetroHeath Medical Center, Cleveland, OH, USA) about the recent post-hoc analysis from the COAST X study (NCT02757352). The analysis was designed to evaluate the efficacy of ixekizumab at week 16 in patients with non-radiographic axial spondyloarthritis (nr-axSpA) with or without baseline HLA-B27 positivity and a disease duration of no more than 5 years. The abstract entitled ‘Response to Treatment with Ixekizumab in Patients with Active Non-Radiographic Axial Spondyloarthritis Based on HLA-B27 Status and Disease Duration’ was presented at ACR Convergence 2020, 5-9 November.
- What is the rationale for the use of ixekizumab in the treatment of non-radiographic axial spondyloarthritis? Tell us about the COAST-X study and its findings, which led to ixekizumab’s approval in this indication. (0:06)
- What were the aims of your recent post-hoc analysis of COAST-X data? (1:19)
- What are the clinical implications of the findings of this analysis? (2:26)
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of virtual ACR Convergence 2020.
Share this Video
Related Videos In Axial Spondyloarthritis
Xenofon Baraliakos, ACR 2022: Bimekizumab in the treatment of active non-radiographic axial spondyloarthritis and ankylosing spondylitis – 52 week findings from BE MOBILE 1 and 2
Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits both IL-17F and IL‑17A, was recently investigated in the phase 3 BE MOBILE 1 (NCT03928704) and BE MOBILE 2 (NCT03928743) clinical trials for active non-radiographic axial spondyloarthritis and ankylosing spondylitis, respectively. touchIMMUNOLOGY were delighted to speak with Dr. Xenofon Baraliakos (Ruhr-Universität Bochum, Bochum, Nordrhein-Westfalen, Germany) to discuss […]
Sofia Ramiro, ACR 2022: Ixekizumab for radiographic axial spondyloarthritis – findings from the COAST-V trial
The COAST-V trial (NCT02696785) investigated the efficacy and safety of ixekizumab in patients with radiographic axial spondyloarthritis who were biological disease-modifying anti-rheumatic drug naïve. It was a pleasure to talk with Dr. Sofia Ramiro (Leiden University Medical Center, Leiden, Netherlands) to discuss the findings in terms of patient reported outcomes at weeks 16 and 52 […]
Xenofon Baraliakos, EULAR 2022: Bimekizumab in Patients with Active Non-Radiographic Axial Spondyloarthritis – BE MOBILE 1
BE MOBILE 1 (ClinicalTrials.gov Identifier: NCT03928704) is a a phase 3 study investigating bimekizumab in the treatment of active non-radiographic axial spondyloarthritis. touchIMMUNOLOGY were delighted to speak with Prof. Xenofon Baraliakos (Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany) around the aims of the BE MOBILE 1 study and the safety and efficacy findings. The abstract ‘Bimekizumab […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!